Biosplice Therapeutics Closes $120 Million in Equity Financing to Advance Its Alternative Splicing Platform
15 avr. 2021 10h55 HE
|
Biosplice Therapeutics, Inc.
New investors include Eventide, aMoon, SymBiosis II, Sands Capital and VeritionProceeds to support Biosplice’s clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its...